Agatolimod
Based on 1 publication(s) in Google Scholar
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.84%
- No. CAS: 525625-52-9
- Peso molecular:7699.00
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Agatolimod
More
Actividad biológica
|
TLR9 |
iNOS |
Agatolimod (10 μM) enhances expression of immunostimulatory cytokine IL-12p70 and chemoattractant cytokines in THP-1 cells, supporting its adjuvant activity[2].
Agatolimod (10 μg/mL; 14 days) increases the radiosensitivity of R-A549 cells, as evidenced by a reduced D0 value of 1.33 Gy in clonogenic assays when combined with radiation[3].
Agatolimod stimulates TLR9 signaling in HEK-Blue-hTLR9 cells with an EC50 of 180 nM[4].
Agatolimod (1-6 μM; 24 h) increases K55 cell surface marker expression in HD11 chicken macrophage cells in a dose-dependent manner (1-3 μM) but does not affect MHC class I or II expression[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AU565, THP-1, activated CD8+ T cells (from healthy HLA-A2+ human donors)
-
Concentration:10 μM (THP-1 pre-treatment)
-
Incubation Time:16 h (THP-1 pre-treatment); 5 d (CD8+ T cell stimulation); 48 h (cytotoxicity assay)
-
Result:Enhanced MamA-specific tetramer staining of CD8+ T cells to 11.1%. Induced 69 ± 10% specific lysis of AU565 cells at an effector-to-target ratio of 40:1.
Observed no significant cytotoxicity on MCF7 cells.
-
Cell Line:radioresistant human lung adenocarcinoma R-A549 cells
-
Concentration:10 μg/mL (for combined treatment with radiation)
-
Incubation Time:12-72 hours
-
Result:Lowered the proliferation rate of R-A549 cells; extended the doubling time to 39.0 hours.
Increased the proportion of R-A549 cells in the G2/M phase to 18.64 ± 0.98% at 24 hours and 28.58 ± 1.34% at 48 hours.
Agatolimod (5 nmol; s.c.; days 7 and 14 after tumor inoculation) enhances the anti-tumor effect of the TRP2 peptide vaccine against TRP2-expressing B16F10 melanoma in mice, though less potently than S-540956[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice bearing Melanoma (female, 6-8 weeks old)[4]
-
Dosage:5 nmol
-
Administration:s.c.; days 7 and 14 after tumor inoculation
-
Result:Showed lower adjuvanticity than S-540956 for enhancing the anti-tumor effect of the TRP2 peptide vaccine; Did not exhibit anti-tumor effect when used alone.
-
Animal Model:C57BL/6J mice bearing Cervical cancer (female, 6-8 weeks old)[4]
-
Dosage:5 nmol
-
Administration:i.m.; days 9 and 16 after tumor inoculation
-
Result:Showed lower adjuvanticity than S-540956 for enhancing the anti-tumor effect of the HPV-E7 peptide vaccine.
Chemical Information
-
No. CAS 525625-52-9
-
Appearance Solid
-
Peso molecular 7699.00
-
Color White to off-white
-
SMILES
[Agatolimod]
-
Synonyms
ODN 2006; PF-3512676; CpG 7909; ODN 7909
-
Sequence
DNA, d(P-thio)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Colloid Interface Sci
Hafnium hydride Nanosheets with reactive oxygen and nitrogen species and cell-free DNA-dual scavenging capabilities for inflammatory bowel disease treatment. [Abstract]2025 Jun 17;699(Pt 2):138222. PMID: 40544617
Solvente y solubilidad
H2O : ≥ 125 mg/mL (16.24 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2242 KB)
Referencias
[1]. Sonoyama T, et al. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine. 2023;41(11):1834-1847. [Content Brief]
[2]. Babaer D, et al. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. Cancers (Basel). 2019;11(5):672. Published 2019 May 14. [Content Brief]
[3]. Yan L, et al. CpG-ODN 7909 increases radiation sensitivity of radiation-resistant human lung adenocarcinoma cell line by overexpression of Toll-like receptor 9. Cancer Biother Radiopharm. 2013;28(7):559-564. [Content Brief]
[4]. Nakagawa T, et al. S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes. Front Immunol. 2021;12:803090. Published 2021 Dec 23. [Content Brief]
[5]. Xie H, et al. CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line. Dev Comp Immunol. 2003;27(9):823-834. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.1299 mL | 0.6494 mL | 1.2989 mL | 3.2472 mL |
| 5 mM | 0.0260 mL | 0.1299 mL | 0.2598 mL | 0.6494 mL | |
| 10 mM | 0.0130 mL | 0.0649 mL | 0.1299 mL | 0.3247 mL | |
| 15 mM | 0.0087 mL | 0.0433 mL | 0.0866 mL | 0.2165 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Agatolimod Related Classifications
HY-146244 Related Classifications
Powered by Bioz
- Agatolimod
- 525625-52-9
- ODN 2006
- PF-3512676
- CpG 7909
- ODN 7909
- ODN2006
- ODN-2006
- PF3512676
- PF 3512676
- PF-3512676
- CpG7909
- CpG 7909
- CpG-7909
- ODN7909
- ODN 7909
- ODN-7909
- Toll-like Receptor (TLR)
- Bacterial
- NO Synthase
- Apoptosis
- TLR9
- TC-1 tumors
- Salmonella enteritidis
- IRAK4
- COVID-19
- TLR6
- lung adenocarcinoma
- IRF5
- breast cancer
- IRF7
- Inhibitor
- inhibitor
- inhibit